Oral IL-23 receptor blocker in ulcerative colitis: what do clinicians think?

In a study published in NEJM, patients with moderate to severe ulcerative colitis achieved clinical response at week 12 significantly more often on icotrokinra than on placebo. It is a peptide that blocks the interleukin-23 receptor and is taken orally once a day. The source description gives no data on longer-term efficacy or safety, so those questions remain open. What shall we discuss: — How convincing is a week-12 response without data on maintenance of effect and long-term safety? — How does blocking the IL-23 receptor with a peptide differ from monoclonal antibodies against the p19 subunit, and could that difference matter clinically? — Could an oral option change the place of targeted therapy in ulcerative colitis management, and which patients might find it most appealing? For USMLE, this connects to the IL-23/Th17 axis in IBD pathogenesis and to comparisons with anti-p19 antibodies in ulcerative colitis and Crohn disease. Full article: drasiiavinograd.com/blog/icotrokinra-ulcerative-colitis-oral-il-23-blo Source: Medical Xpress medicalxpress.com/news/2026-10-daily-oral-icotrokinra-outperforms-plac